Lifelong Wealth Advisors Inc. Invests $849,000 in Eli Lilly and Company (NYSE:LLY)

Lifelong Wealth Advisors Inc. purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,100 shares of the company's stock, valued at approximately $849,000. Eli Lilly and Company comprises 0.4% of Lifelong Wealth Advisors Inc.'s holdings, making the stock its 28th biggest holding.

Other institutional investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after purchasing an additional 20 shares during the period. FPC Investment Advisory Inc. raised its stake in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after buying an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. purchased a new stake in Eli Lilly and Company in the fourth quarter worth about $48,000. Compass Financial Services Inc bought a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $50,000. Finally, Fiduciary Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $58,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on LLY shares. Citigroup lowered their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Morgan Stanley decreased their price target on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a research note on Wednesday, April 9th. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a report on Thursday, January 16th. Finally, StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Two research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $1,012.00.

Eli Lilly and Company Stock Performance

LLY stock traded up $106.80 on Friday, hitting $841.70. The company had a trading volume of 10,843,294 shares, compared to its average volume of 3,427,404. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The stock has a market cap of $798.08 billion, a price-to-earnings ratio of 71.88, a P/E/G ratio of 1.40 and a beta of 0.51. The stock's 50-day simple moving average is $829.09 and its 200 day simple moving average is $819.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.